Education
About Us
Working with TipRanks
Follow Us
Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,147.55 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹234.53B
Enterprise Value₹227.93B
Total Cash (Recent Filing)₹11.64B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)44.1
Beta0.69
Next Earnings
May 14, 2026EPS Estimate
7.4Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.46
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained gross (~60.8%) and net (~19.8%) margins indicate durable operating efficiency and pricing power in core diagnostics. High margins support reinvestment in labs and technology, help absorb cost shocks, and underpin long-term cash generation and profitability stability.
Strong Cash GenerationConsistent operating cash flow aligned with net income and rising free cash flow demonstrates robust cash conversion and capital discipline. This liquidity profile funds organic expansion, lab upgrades, and working capital without heavy reliance on external financing over the medium term.
Conservative Balance SheetA low debt-to-equity posture and high equity financing reduce refinancing and solvency risk, preserving financial flexibility. Conservative leverage supports steady capex, potential opportunistic M&A, and resilience across cycles, enhancing the company's strategic optionality over 2–6 months.
Bears Say
Moderate Return On EquityA stated need to improve ROE suggests capital and assets are not yet delivering top-tier shareholder returns. Persistently moderate ROE can limit EPS growth and investor returns unless offset by faster revenue expansion, better asset utilization, or higher operating leverage.
Modest Revenue GrowthRevenue expansion near ~10.8% is steady but modest for a scalable diagnostics business. Slower top-line growth may limit operating leverage and market-share gains, requiring continued margin efficiency or new service channels to materially boost long-term earnings growth.
Revenue Concentration On Volumes & MixDependence on fee-for-service testing ties revenues to patient volumes, test mix and network density. Structural exposure to utilization shifts, negotiated B2B pricing, or slower volume growth can pressure utilization and margins, limiting durable margin expansion without diversification.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1147.55 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹234.53B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is May 14, 2026 which is in 87 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.455 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹1.17.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Overvalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.4.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.455 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
Technical Analysis
Jupiter Life Line Hospitals Ltd.
―
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―